First Wave to merge with Im­muno­genX; Cali­way rais­es $100M; New deals for Re­play’s Sye­na

First Wave Bio­Phar­ma’s merg­er plans: The Flori­da biotech said it plans to merge with Im­muno­genX, an­oth­er gas­troin­testi­nal dis­eases com­pa­ny that is de­vel­op­ing an oral can­di­date known as latiglute­nase for celi­ac dis­ease. Af­ter the deal clos­es, First Wave said it ex­pects to an­nounce that a glob­al drug­mak­er is pay­ing for the com­mer­cial rights to the drug can­di­date as well as new fi­nanc­ing from undis­closed in­sti­tu­tion­al in­vestors. The Phase III tri­als are ex­pect­ed to be­gin in the sec­ond half of next year. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER